Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

CombiPatch

Last reviewed on RxList: 6/19/2019
CombiPatch Side Effects Center

Last reviewed on RxList 6/19/2019

CombiPatch (estradiol, norethindrone acetate transdermal system) is a combination of female hormones used to treat the symptoms of menopause such as feelings of warmth in the face, neck and chest, or sudden intense spells of heat and sweating ("hot flashes" or "hot flushes"); to treat vulvar and vaginal changes (itching, burning, dryness in or around the vagina, difficulty or burning with urination) caused by menopause; and to replace estrogen in conditions such as hypogonadism, removal of the ovaries, or primary ovarian failure that result in a lack of estrogen. Common side effects of CombiPatch include:

  • skin redness/irritation/rash at the application site,
  • abdominal pain,
  • nausea,
  • vomiting,
  • bloating,
  • breast tenderness or enlargement,
  • weakness,
  • swelling of the hands or feet,
  • spotty darkening of the skin (particularly on the face),
  • difficulty wearing contact lenses,
  • vaginal irritation or discomfort,
  • changes in menstrual cycle,
  • painful menstruation,
  • breakthrough bleeding,
  • headache, or
  • weight changes.

Tell your doctor if you have serious side effects of CombiPatch including:

Two CombiPatch transdermal delivery systems are available: 0.05 mg estradiol with 0.14 mg NETA per day (9 sq cm) and 0.05 mg estradiol with 0.25 mg NETA per day (16 sq cm). The lowest effective dose should be used. CombiPatch may interact with anticoagulants (blood thinners). Tell your doctor all medications you use. CombiPatch must not be used during pregnancy. If you become pregnant or think you may be pregnant, tell your doctor. This medication passes into breast milk. It may reduce the quality and amount of breast milk produced. Consult your doctor before breastfeeding.

Our CombiPatch (estradiol, norethindrone acetate transdermal system) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

If menopause occurs in a woman younger than ___ years, it is considered to be premature. See Answer
CombiPatch Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Remove the skin patch and call your doctor at once if you have:

  • heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;
  • increased blood pressure--severe headache, blurred vision, pounding in your neck or ears, anxiety, nosebleed;
  • signs of a stroke--sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance;
  • signs of a blood clot--sudden vision loss, stabbing chest pain, feeling short of breath, coughing up blood, pain or warmth in one or both legs;
  • swelling or tenderness in your stomach;
  • jaundice (yellowing of the skin or eyes);
  • unusual vaginal bleeding, pelvic pain;
  • a breast lump;
  • memory problems, confusion, unusual behavior; or
  • high levels of calcium in your blood--nausea, vomiting, constipation, increased thirst or urination, muscle weakness, bone pain, lack of energy.

Common side effects may include:

  • nausea, vomiting, stomach cramps;
  • bloating, swelling, weight gain;
  • breast pain;
  • light vaginal bleeding or spotting;
  • vaginal itching or discharge;
  • headache;
  • thinning scalp hair; or
  • redness or irritation where the patch is worn.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for CombiPatch (Estradiol, Norethindrone Acetate Transdermal System)

SLIDESHOW

What Is Osteoporosis? Treatment, Symptoms, Medication See Slideshow
CombiPatch Professional Information

SIDE EFFECTS

See BOX WARNING, WARNINGS, and PRECAUTIONS.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Table 9. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch

 
  VASOMOTOR SYMPTOM STUDIES
CombiPatch
0.05/0.14
mg per day†
CombiPatch
0.05/0.25
mg per day
Placebo
n=113 n=112 n=107
Body as a Whole 46% 48% 41%
  Abdominal Pain 7% 6% 4%
  Accidental Injury 4% 5% 8%
  Asthenia 8% 12% 4%
  Back Pain 11% 9% 5%
  Flu Syndrome 9% 5% 7%
  Headache 18% 20% 20%
  Pain 6% 4% 9%
Digestive 19% 23% 24%
  Diarrhea 4% 5% 7%
  Dyspepsia 1% 5% 5%
  Flatulence 4% 5% 4%
  Nausea 11% 8% 7%
Nervous 16% 28% 28%
  Depression 3% 5% 9%
  Insomnia 3% 6% 7%
  Nervousness 3% 5% 1%
Respiratory 24% 38% 26%
  Pharyngitis 4% 10% 2%
  Respiratory Disorder 7% 12% 7%
  Rhinitis 7% 13% 9%
  Sinusitis 4% 9% 9%
Skin and Appendages 8% 17% 16%
  Application Site Reaction* 2% 6% 4%
Urogenital 54% 63% 28%
  Breast Pain 25% 31% 7%
  Dysmenorrhea 20% 21% 5%
  Leukorrhea 5% 5% 3%
  Menstrual Disorder 6% 12% 2%
  Papanicolaou Smear Suspicious 8% 4% 5%
  Vaginitis 6% 13% 5%
Represents milligrams of estradiol/NETA delivered daily by each system.
*Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles.

Table 10. All Adverse Reactions Regardless of Relationship Reported at a Frequency of Greater than or Equal to 5 percent with CombiPatch

 
  ENDOMETRIAL HYPERPLASIA STUDIES
CombiPatch
0.05/0.14
mg per day
CombiPatch
0.05/0.25
mg per day
Vivelle
0.05
mg per day
n=325 n=312 n=318
Body as a Whole 61% 60% 59%
  Abdominal Pain 12% 14% 16%
  Accidental Injury 10% 11% 8%
  Asthenia 10% 13% 11%
  Back Pain 15% 14% 13%
  Flu Syndrome 14% 10% 7%
  Headache 25% 17% 21%
  Infection 5% 3% 3%
  Pain 19% 15% 13%
Digestive 42% 32% 31%
  Constipation 2% 5% 3%
  Diarrhea 14% 9% 7%
  Dyspepsia 8% 6% 5%
  Flatulence 7% 5% 6%
  Nausea 8% 12% 11%
  Tooth Disorder 6% 4% 1%
Metabolic and Nutritional Disorders 12% 13% 11%
  Peripheral Edema 6% 6% 5%
Musculoskeletal 17% 17% 15%
  Arthralgia 6% 6% 5%
Nervous 33% 30% 28%
  Depression 8% 9% 8%
  Dizziness 6% 7% 5%
  Insomnia 8% 6% 4%
  Nervousness 5% 6% 3%
Respiratory 45% 43% 40%
  Bronchitis 5% 3% 4%
  Pharyngitis 9% 9% 8%
  Respiratory Disorder 13% 9% 13%
  Rhinitis 19% 22% 17%
  Sinusitis 10% 12% 12%
Skin and Appendages 38% 37% 31%
  Acne 4% 5% 4%
  Application Site Reaction* 20% 23% 17%
  Rash 6% 5% 3%
Urogenital 71% 79% 74%
  Breast Enlargement 2% 7% 2%
  Breast Pain 34% 48% 40%
  Dysmenorrhea 30% 31% 19%
  Leukorrhea 10% 8% 9%
  Menorrhagia 2% 5% 9%
  Menstrual Disorder 17% 19% 14%
  Vaginal Hemorrhage 3% 6% 12%
  Vaginitis 9% 13% 13%
Represents milligrams of estradiol/NETA delivered daily by each system.
*Application site reactions includes localized bleeding, bruising, burning, discomfort, dryness, eczema, edema, erythema, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, skin discoloration, skin pigmentation, swelling, urticaria, and vesicles.

Postmarketing Experience

The following additional adverse reactions have been identified during post-approval use of CombiPatch. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary System

Endometrial hyperplasia, endocervical polyp, uterine leiomyomata, fallopian tube cyst, uterine spasms.

Breast

Breast cancer.

Cardiovascular

Hypertension, varicose veins.

Gastrointestinal

Jaundice cholestatic, cholelithiasis, gall bladder disorder, transaminases increased.

Skin

Skin discoloration.

Central Nervous System

Affect lability, libido disorder, migraine, vertigo, paresthesia.

Miscellaneous

Angioedema, hypersensitivity, weight increased.

Read the entire FDA prescribing information for CombiPatch (Estradiol, Norethindrone Acetate Transdermal System)

Related Resources for CombiPatch

Related Drugs

Read the CombiPatch User Reviews »

© CombiPatch Patient Information is supplied by Cerner Multum, Inc. and CombiPatch Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

QUESTION

If menopause occurs in a woman younger than ___ years, it is considered to be premature. See Answer

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW